Related Experiment Video
Updated: Sep 22, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Emerging antibody-based therapies for the treatment of acute myeloid leukemia
Linus Angenendt1, Jan-Henrik Mikesch2, Christoph Schliemann2
1Department of Medicine A, University Hospital Münster, Münster, Germany; Department of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland.
Abstract:
The development of antibody-based therapeutics for patients with acute myeloid leukemia (AML) has long been hampered due to the shared expression of antigens on leukemic blasts and hematopoietic stem and progenitor cells (HSPC). Nevertheless, the first antibody-drug conjugate has been approved for the treatment of AML in the recent years. In addition, multiple antibody-based therapeutics including antibody-drug conjugates, bispecific antibodies and immunocytokines are currently being developed in clinical trials with some of them demonstrating encouraging results alone and/or in combination with current standard therapies. In this review we discuss current concepts of antibody-based therapies and results from emerging antibody-based therapeutics for the treatment of AML.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy

